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Objective:To study the perception of informed consent among various raters for thrombol-
ysis in acute ischemic stroke patients receiving intravenous tissue plasminogen activator
(IV-tPA). Methods:Twenty randomly selected videotaped telestroke consultations of acute
stroke patients administered IV-tPA were retrospectively reviewed. Adequacy of informed
consent was reviewed by five raters: a neurologist and emergency physician who rou-
tinely treat stroke, a medical risk management paralegal, a bioethicist, and a lay person.
Raters assessed the quality of the informed consent presentation by the treating physician
and the degree of understanding demonstrated by the patient/family authorizing consent.
Factors associated with adequacy of consent were analyzed. Results: Consent was rated
as adequately understood by the patient-family in 78.6% cases. Agreement between all
five raters with regard to the patient-family understanding of consent was poor and also
between the subgroups of non-physician and physician (all k < 0.20). Similarly, the quality
of the physician consent process was poor for agreement between all five raters (k =0.07)
or between the subgroup of the three non-physician raters (k =−0.06) and fair between the
two physician raters (k =0.24). The legal reviewer and the bioethicist rated the physician
consent process as being of lower quality than did the two physicians and the layperson.
Conclusion: Despite high variability in the perception of informed consent among raters
in this time-sensitive clinical situation, almost 80% of patients were rated by all reviewers
as having adequate understanding of risks and benefits of tPA. This suggests the need for
a standardized but brief tPA consent process that includes patient/family demonstration of
understanding.
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INTRODUCTION
Intravenous tissue plasminogen activator (IV-tPA) was approved
in 1996 by the FDA for the treatment of acute ischemic stroke
within 3 h of symptom onset (FDA Center for Biologics Eval-
uation and Research, 1996). Although written consent is not
required prior to drug administration, the American Heart Asso-
ciation Guidelines recommend that, the potential risks and
benefits should be explained to the patient and their fam-
ily (Adams et al., 2003). These potential benefits of IV-tPA,
must be weighed against the potential risks prior to treat-
ment decision (The NINDS t-PA Stroke Study Group, 1995,
1997).
Physicians are ethically obligated to explain these specific
issues to the patient (or legally authorized representative if the
patient lacks capacity) in plain language that is easily under-
stood. This communication process in which patients receive
relevant information related to their diagnosis and treatment
options and subsequently make an informed decision to autho-
rize a specific treatment is captured under the domain of
“informed consent” (Paterick et al., 2008; Schenker et al., 2011).
The key elements of informed consent include disclosure of
information including risks, benefits, and alternatives, voluntary
choice, and decisional competence (White-Bateman et al., 2007;
Schenker et al., 2011). However, in the heat of the moment when
every minute of delay reduces the chances of recovery in acute
stroke, the informed consent process may become compressed or
distorted.
Telemedicine-enabled acute stroke (telestroke) consultation to
a network of referring hospitals in New England has been a routine
part of acute stroke care for our faculty and fellows for the past
decade. In this setting, all telestroke consultations are recorded
and so this platform provides an excellent opportunity to study
the consent process without the intrusive presence of a camera,
tape recorder, or third party analyst distorting the process. These
video recordings allow for multiple raters to review the same con-
sent discussions and compare their assessments. We sought to
determine the perception of the nature and quality of the consent
for IV thrombolysis in real practice, from both the patient and
provider perspective by analyzing a series of recorded telestroke
consultations.
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MATERIALS AND METHODS
This was a retrospective review of the informed consent process in
acute ischemic stroke patients who received telestroke consultation
for administration of IV-tPA. All patients presented to a referring
outside hospital within 3 h of symptom onset and were evaluated
by video at our tertiary care center. The study was approved by our
local Institutional Review Board.
TELESTROKE SYSTEM
The Massachusetts General Hospital TeleStroke program consists
of 26 member hospitals in the greater New England area, the details
of which have been previously described (Schwamm et al., 2004;
Pervez et al., 2010). Briefly, it uses a decision-supported model of
live, interactive videoconferencing coupled with remote review of
brain images via teleradiology to enable the evaluation of remotely
located acute stroke patients for IV-tPA eligibility. Clinical verbal
consent is always obtained from the patient or surrogate prior
to thrombolysis. The full consultation encounter is recorded in a
standard viewable video format, and was made available for review.
Patients are consented for participation in the telestroke consul-
tation including for teaching and research purposes related to the
telestroke encounter.
PATIENT SELECTION AND TELESTROKE CASE REVIEW
Video recordings of 20 patients who received IV-tPA after tele-
stroke consultations at six outside hospitals between May 2007 and
October 2008 were randomly selected for evaluation by reviewers
from 67 patients who received IV-tPA during this period. There
were no patients who declined treatment. The physician perform-
ing informed consent via TeleStroke consultation varied among
the 20 cases. Adequacy of informed consent was assessed by five
independent raters: a neurologist (MD1) and emergency physi-
cian (MD2) who routinely treat stroke, a medical risk management
legal advisor, a bioethicist, and a lay person without medical train-
ing or experience in stroke or consent. Reviewers were not involved
in the original patient encounter and were blinded to the other
reviewers’ ratings and any details about patient outcomes. Fur-
thermore, the study was retrospective in nature and we chose
recordings taken prior to any discussion of the proposed study or
its design to avoid any contamination of the consent process. In all
cases the patient, a legally authorized representative or surrogate,
or both, were involved in the consent process. Cases were excluded
by the reviewers if the entire consent process was not completely
captured on the video (n= 3), or if technical limitations in audio
or video quality related to patient/family or provider comments
during the consent process prevented any reviewers from assigning
scores (n= 3). Numbered video recordings (in Windows Media
Player or QuickTime format) of each consultation were provided
to reviewers. These media formats have free viewing software that
permit the user to view any section of the recording, and to pause
or re-play, as desired. There were no limits placed on how reviewers
evaluated the recordings, or how often they reviewed them prior
to scoring.
To avoid biasing the reviewers, the following minimal instruc-
tions were given rather than a checklist of individual elements of
informed consent: “Please watch the following video clips and
based on your background and experience rate the quality of
consent seen on the video. There are two aspects of the consent to
be rated: (1) Did the MD explain the risks and benefits? (2) Did
the patient or caregiver appear to understand the risks and ben-
efits? Score each question on the following scale: 0= no, 1= yes
but needs improvement, 2= adequate, 3= exceeds expectations.”
OUTCOMES AND STATISTICAL ANALYSIS
As described above, a four-point Likert scale (Likert, 1932) was
developed for the purpose of rating two distinct aspects of the
consultation process: the quality of informed consent process as
presented by the treating physician and the degree of understand-
ing demonstrated by the patient or family member authorizing
consent. This ordinal numerical scale (0= insufficient, 1= poor,
2= adequate, and 3= exceeds expectations) was used to rate all
cases. Acceptable understanding of the consent process by the
patient or family was defined as occurring when Likert scores were
≥2. We chose an even-point scale in order to construct a forced-
choice scale where neutral ratings of the consent process were
not possible. When numerical Likert scale scores were grouped
across raters, mean values are reported as appropriate. Likert
scale scores grouped across cases for each individual rater are
reported as median values. Factors potentially associated with
adequacy of consent (age, sex, education level, duration of con-
sent, NIHSS, patient, or family providing consent) were analyzed,
however sample size was too low to conduct any formal compar-
ative testing. Levels of agreement between raters was determined
by un-weighted kappa values, with agreement defined as poor
(k < 0.20), fair (k = 0.20–0.39), moderate (k = 0.40–0.59), good
(k = 0.60–0.79), and excellent (k = 0.80–1.0). Statistical analysis
was performed using JMP software (version 8, SAS Corporation).
RESULTS
All patients were English speaking with a mean age of
69± 15.8 years and median initial NIHSS score over telestroke
of 11.5 points. Family members gave primary consent in 50%
of cases. The duration (mean± SD) of the consent discussion
was 2.7± 1.3 min. The distribution of scores varied for the two
categories by different raters (Figure 1), and there were notable
similarities among certain groups of raters.
Acceptable understanding of the consent process occurred in
11/14 (78.6%) cases. In the remaining three cases, the mean of all
numerical reviewer Likert scores was <2. There were no differ-
ences in baseline characteristics between those subjects in whom
patient-family understanding of consent was rated as acceptable
vs. unacceptable (Table 1), however, the mean consent duration
was longer in the acceptable consent group (2.8 vs. 1.8 min) and
the time elapsed from last seen well to thrombolysis tended to be
shorter in this group (126.4 vs. 159 min). Acceptable quality of the
physician consent process was defined similarly as a mean Likert
score ≥2. Compared to those cases in which the treating physi-
cian was rated as not providing acceptable consent, there were no
differences in patient characteristics (Table 2).
The level of agreement between raters with regard to the
patient-family understanding of consent, as measured by the
kappa statistic, was poor between all five raters, between the
subgroup of the three non-physician raters, and between the
two physician raters (all k < 0.20). Similarly, the quality of the
Frontiers in Neurology | Teleneurology August 2012 | Volume 3 | Article 128 | 2
Thomas et al. Informed consent for IV-tPA
FIGURE 1 | Distribution of scores among raters. Median Likert score
ratings are shown for five raters. The Likert scale rating consists of an
ordinal numerical value ranging from 0= insufficient, 1=poor,
2= adequate to 3= exceeds expectations. The numbers depicted
vertically along the bars show the median Likert score with interquartile
range in parenthesis. MD1 is neurologist; MD2 is emergency physician.
“MD consent” refers to quality of the consent process provided by the
treating physician. “Pt-Fam consent” refers to adequacy of the
understanding demonstrated by the patient and/or family authorizing
consent.
physician consent process was poor for agreement between all
five raters (k = 0.07) or between the subgroup of the three non-
physician raters (k =−0.06) and fair between the two physician
raters (k = 0.24). When the ratings were analyzed as overall groups,
regardless of rater subgroups, the median [IQR] ratings of patient-
family understanding of consent and physician consent process did
not differ (2[2–2] vs. 2[2–3]).
When evaluating the relationship between the quality of
patient-family understanding to that of the physician consent
process, a pattern was observed. Cases in which patient-family
understanding was rated acceptable (n= 11) had a corresponding
rating of the physician consent process in the acceptable range
(mean Likert 2.30) as well, whereas those in which patient-family
understanding was rated unacceptable (n= 3) had a rating of the
physician consent process in the unacceptable range (mean Likert
1.60) as well. This mean Likert scale score difference was 0.70.
There were observed differences between types of raters when
the quality of the physician consent process was analyzed by
median Likert scores assigned. The legal reviewer (1) and the
bioethicist (2) rated the physician consent process as being of lower
quality than did the two physicians and the layperson (3). When
the quality of patient-family understanding was analyzed in a sim-
ilar manner, the lay person rated this lower than the other raters
(1.5 vs. 2).
DISCUSSION
The major findings from this study are that there is high variabil-
ity among raters, both physician and non-physicians, regarding the
perceived quality of informed consent for thrombolysis in acute
stroke and that the conversation regarding informed consent is
generally quite brief (mean duration<3 min). Despite this, almost
80% of patients were rated by all reviewers as having adequate
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Table 1 | Patient characteristics for all patients and patients with
acceptable vs. unacceptable patient/family consent.
All
patients
(n=14)
Pt-Fam
acceptable
consent
(n=11)
Pt-Fam
unacceptable
consent
(n=3)
Age (mean years±SD) 69±15.8 68.8±17.3 69.7±11.1
Female 5 (35.7%) 5 (45.5%) 0 (0%)
High school graduate
(n=10)
6 (60%) 4 (50%) 2 (100%)
History of hypertension 12 (85.7%) 9 (81.8%) 3 (100%)
History of diabetes
mellitus
3 (21.3%) 2 (18.2%) 1 (33.3%)
History of hyperlipidemia 7 (50%) 4 (36.4%) 3 (100%)
Family present for consent 11 (78.6%) 9 (81.8%) 2 (66.7%)
Person authorizing consent
Patient 4 (28.6%) 3 (27.3%) 1 (33.3%)
Family 7 (50%) 6 (54.6%) 1 (33.3%)
Both 3 (21.4%) 2 (18.2%) 1 (33.3%)
Duration of consent
(minutes±SD; n=13)
2.7±1.3 2.8±1.3 1.8±1.1
Time last seen well to tPA
(minutes±SD)
133.4±21.9 126.4±17.6 159.0±18.1
NIHSS [median (IQR)] 11.5 (7–17.3) 11 (7–17) 12 (11–18)
NIHSS item 9: best
language [median (IQR)]
0.5 (0–2.3) 0 (0–3) 1 (0–2)
Table 2 | Patient characteristics for acceptable vs. unacceptable
treating MD consent.
MD acceptable
consent (n=12)
MD unacceptable
consent (n=2)
Age (mean years±SD) 67.9±16.8 75.5±6.36
Female 5 (41.7%) 0 (0%)
High school graduate (n=10) 5 (55.6%) 1 (100%)
History of hypertension 10 (83.3%) 2 (100%)
History of diabetes mellitus 3 (25%) 0 (0%)
History of hyperlipidemia 5 (41.7%) 2 (100%)
Family present for consent 10 (83.8%) 1 (50%)
Person authorizing consent
Patient 3 (25%) 1 (50%)
Family 6 (50%) 1 (50%)
Both 3 (25%) 0 (0%)
Duration of consent
(minutes±SD; n=13)
2.8±1.3 1.1±0.0
Time last seen well to tPA
(minutes±SD)
130.5±22.0 150.5±14.8
NIHSS [median (IQR)] 11.5 (7–16) 14.5 (11–18)
NIHSS item 9: best language
[median (IQR)]
0.5 (0–2.8) 1 (0–2)
understanding regarding the risks and benefits of thrombolytic
therapy.
There is a need to better understand, improve, and standardize
the process of informed consent for thrombolysis in acute stroke.
Studies of the adequacy of the consent process have largely focused
on the extent of the risk explanation by retrospective review of
written documentation (Jeyaseelan et al., 2010; Patel et al., 2010;
Siddins et al., 2009; Ahmad et al., 2009) and exist mostly in the
surgical field. Other studies have used interviews or written ques-
tionnaires to focus on the patient’s perceptions of consent, most
of which reveal that patients perceive the consent process to be
inadequate and often sign consent forms without reading them
(Lavelle-Jones et al., 1993; Kay and Siriwardena, 2001). In com-
paring the consent process for elective vs. emergent procedures,
patients undergoing emergent procedures are less likely to have
read or understood the consent form and are more likely to report
feeling frightened by the consent process (Akkad et al., 2004).
Therefore, further improvements in the consent process are needed
especially in emergent circumstances (Akkad et al., 2004).
Cognitive capacity related to decision making may be impaired
in emergency situations. Studies of patients with acute myocardial
infarction involved in experimental trials demonstrate that phys-
ical and emotional stress alone may hinder understanding of the
consent process (Williams et al., 1997, 2003; Smithline et al., 1999;
Agard et al., 2001). A large proportion of acute stroke patients are
unable to provide consent for enrollment in experimental acute
stroke trials due to acute cognitive impairment (Demarquay et al.,
2005; Kane et al., 2006). Additional obstacles of obtaining con-
sent in acute stroke may include cognitive impairment due to the
stroke itself. The stroke patient may have impaired communica-
tion due to dysarthria or aphasia, may be unaware of the illness
due to anosognosia, or may have an altered level of consciousness
(White-Bateman et al., 2007; Ciccone et al., 2001). These diffi-
culties compounded with the emergent nature of the illness and
need for rapid treatment, make consent challenging, especially in
patients with greater cognitive deficits.
Retrospective approaches to studying consent adequacy, most
commonly by review of documented risks on the consent form
(Ahmad et al., 2009; Siddins et al., 2009; Jeyaseelan et al., 2010; Patel
et al., 2010) or by immediate or delayed patient interview or ques-
tionnaires (Lavelle-Jones et al., 1993; Kay and Siriwardena, 2001)
are limited in gaging the true nature of the consent encounter.
Written documentation may not reflect the entire verbal exchange
or interaction. Furthermore, patient recall of the consent process
may be biased. For acute ischemic stroke, our study is the first to
date using real-time unedited videos from telemedicine encoun-
ters to review the perceived quality of the informed consent process
among various raters. As our service uses telestroke consultation
as part of our routine clinical practice and the recording of the
consults is an unobtrusive by-product of teleconsultation, these
recordings likely reflect true clinical practice in a way that would
be difficult or impossible to capture during in-person acute stroke
evaluations at our hospital.
Informed consent may be perceived differently by different
groups of people. For example, there may be systematic dif-
ferences in perception between physicians, medico-legal experts,
patients, and laypeople as to the adequacy of the risks and ben-
efits as explained by the doctor, or the level of understanding
evidenced by the patient or family. Our finding of consistently
lower ratings of the physician consent process by the two reviewers
with professional training in informed consent doctrine supports
Frontiers in Neurology | Teleneurology August 2012 | Volume 3 | Article 128 | 4
Thomas et al. Informed consent for IV-tPA
this hypothesis. They may hold the physician to a more strict set
of ethical or legal standards and may not relax those standards
despite the time constraints associated with IV-tPA treatment.
Yet despite rater variability, almost 80% of patient and/or fam-
ilies were rated as having adequate understanding of the consent
process. This is in contrast to a previous study regarding informed
consent in outpatient practice which reported much lower rates
of adequate consent (Braddock et al., 1999). In this study, which
analyzed over 1000 non-blinded audio taped patient-physician
discussions, only 9% of encounters met the very strict definition
of complete informed consent (Braddock et al., 1999). This differ-
ence in rates is likely due to differing objectives between studies.
The aim of our study was to explore different perspectives on the
actual practice of informed consent among reviewers of different
medical and non-medical backgrounds rather than asses the rates
of adherence to a strict set of defined criteria.
Furthermore, in certain situations, fulfilling all of the elements
of informed consent may not be possible or desirable (Hall and
Schneider,2000). Specifically, for acute stroke thrombolysis, a deci-
sion to treat must be reached quickly after a briefer version of the
consent process. Experience in the stroke clinical trial literature
suggests that the use of strict consent criteria, or those that require
patient or family signature on a consent form, may exclude a large
percentage of potential subjects from trial enrollment (Tu et al.,
2004; Demarquay et al., 2005; Kane et al., 2006). Similarly, in clin-
ical practice, the informed consent conversation should convey
information in a manner that is succinct but understandable to
allow for treatment of the maximal number of potentially eligi-
ble patients. Furthermore, some studies have suggested that more
complete and formal informed consent processes may not improve
patient understanding (Stanley et al., 1998) and may provide more
information than the patient desires (Degerliyurt et al., 2010). Due
to these considerations, a standardized consent protocol for acute
stroke thombolysis may require broad consensus from a multi-
disciplinary group of experts similar to raters in this study. See
Table 3 for a proposed telemedicine consent process based on the
authors’ experience at their institution.
We believe that the ideal tPA consent process should be brief
and include the description of an ischemic stroke, the proposed
treatment, and the risks associated with that treatment. These
elements should be explained clearly and in plain language that
is easily understood by the patient and family. There should be
a pause to determine whether the patient/family do understand
what the provider has explained by asking them to rephrase what
they understand. There should also be an opportunity to ask
questions. Based on this discussion, a decision to proceed or not
proceed with thrombolysis should be made. We do not favor a
strict consent criteria as it may be detrimental to the time critical
process.
Specific factors adversely affecting quality of informed consent
in patients undergoing surgical procedures have been reported,
and include older age, lower IQ, and impaired cognition (Lavelle-
Jones et al., 1993). We examined a number of potential factors asso-
ciated with adequacy of consent in stroke thrombolysis, however
we did not have the power to detect any differences.
The only known prior study related to the process of informed
consent for thrombolytic therapy for acute ischemic stroke focused
Table 3 | Sample provider script for obtaining patient’s consent forTPA
thrombolysis.
The doctors who have examined you (or your family member) believe
that an ischemic stroke is happening right now. This condition occurs when
blood flow to the brain is blocked, usually by a blood clot blocking the
arteries that deliver blood to the brain. Studies in thousands of patients
with strokes like yours have shown that when the clot-dissolving drug
alteplase (also called “tpa”) is given intravenously, patients have a much
better chance of recovering to normal, and living at home after a stroke.
Even though there is a small increased chance of bleeding, the chances of
benefit from the treatment are 6–10 times greater than the risks of harm
from the treatment. The faster the treatment is started, the better your
chances of recovery.
Do you understand what I have explained to you?
Do you have any questions?
Please use your own words to repeat back to me what I have explained to
you. (If there are any misunderstandings, telemedicine physician should
correct them and repeat this step.)
Would you like to proceed with this treatment?
Proceed with thrombolysis
on the frequency of documentation of informed consent in clin-
ical practice (Rosenbaum et al., 2004). In this retrospective study,
a substantial number of patients (15%) had no documented dis-
cussion of consent for IV-tPA therapy. Furthermore, surrogates
provided consent in 63% of cases where patients still had evidence
of capacity for consent (Rosenbaum et al., 2004). This mirrors our
findings in that the majority of encounters had some level of fam-
ily involvement in the consent process. In our study, there were no
patients lacking capacity for consent who did not have a surrogate
present. Any future standardized consent protocol will likely not
apply to the subgroup of these individuals.
Our study has several limitations. We cannot exclude the pos-
sibility that our small sample size may have precluded us from
detecting associations related to adequacy of consent. We could
not assess the level of agreement between raters of the same back-
ground because we deliberately chose raters of different training,
background, and experience. The level of agreement between the
two physicians of different specialties and the two raters with pro-
fessional training in informed consent suggests that the findings of
each rater type might reflect the ratings of that group more broadly,
but that will require additional studies. These findings may not be
generalizable to other practice settings or consent performed by
other providers (non-stroke physicians). There may have been por-
tions of the consent interaction that were not visible on the video
footage available to reviewers which may have affected the ratings
of quality. We did not randomize the order of video review so it
is possible that earlier videos had an effect on the ratings of later
viewed videos. Finally, video-based informed consent may differ
compared to consent obtained through in-person consultation.
Direct comparison of these methods should be performed in
future studies.
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In summary, high variability exists among reviewers in the
perceived quality of informed consent in the time-sensitive clin-
ical setting of thrombolysis for acute stroke. However, despite
these challenging circumstances, the majority of patients were
rated by all reviewers as having adequate understanding of risks
and benefits of IV-tPA treatment. The telestroke consent scenario
likely mirrors real-world clinical practice. Although a formal writ-
ten informed consent is not required for the administration of
IV-tPA, this study suggests a potential role for implementing a
standardized brief IV-tPA verbal consent process that incorpo-
rates a demonstration of patient/family understanding and desire
to proceed.
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